[BNT162b2 mRNA新冠疫苗接种后免疫性血小板减少症]
[Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
作者信息
Matsumura Ayako, Katsuki Kengo, Akimoto Masahiro, Sakuma Takayuki, Nakajima Yuki, Miyazaki Takuya, Fujisawa Shin, Nakajima Hideaki
机构信息
Department of Hematology, Yokohama City University Medical Center.
Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine.
出版信息
Rinsho Ketsueki. 2021;62(11):1639-1642. doi: 10.11406/rinketsu.62.1639.
Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic until today, but treatment options remain limited. COVID-19 vaccination is expected to decrease the number of patients with COVID-19 worldwide. In Japan, two types of mRNA COVID-19 vaccine, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna), have been approved and administered. However, their side effects remain poorly elucidated. This paper presents two cases of immune thrombocytopenia (ITP) after BNT162b2 mRNA COVID-19 vaccination. Whether or not ITP is triggered by the vaccination or not is difficult to identify. Further investigation with a large number of cases is warranted to clarify the side effects of BNT162b2 mRNA COVID-19 vaccination.
截至今日，2019冠状病毒病（COVID-19）已演变成一场全球大流行，但治疗选择仍然有限。预计COVID-19疫苗接种将减少全球COVID-19患者的数量。在日本，两种mRNA COVID-19疫苗，BNT162b2（辉瑞/生物新技术公司）和mRNA-1273（莫德纳公司）已获批准并投入使用。然而，它们的副作用仍未得到充分阐明。本文介绍了两例接种BNT162b2 mRNA COVID-19疫苗后发生免疫性血小板减少症（ITP）的病例。很难确定ITP是否由疫苗接种引发。有必要通过大量病例进行进一步调查，以阐明BNT162b2 mRNA COVID-19疫苗接种的副作用。
Zotero 插件